204 related articles for article (PubMed ID: 23785176)
1. Substrate-dependent inhibition of human MATE1 by cationic ionic liquids.
Martínez-Guerrero LJ; Wright SH
J Pharmacol Exp Ther; 2013 Sep; 346(3):495-503. PubMed ID: 23785176
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the inhibitory effects of N-butylpyridinium chloride and structurally related ionic liquids on organic cation transporters 1/2 and human toxic extrusion transporters 1/2-k in vitro and in vivo.
Cheng Y; Martinez-Guerrero LJ; Wright SH; Kuester RK; Hooth MJ; Sipes IG
Drug Metab Dispos; 2011 Sep; 39(9):1755-61. PubMed ID: 21646436
[TBL] [Abstract][Full Text] [Related]
3. Substrate-dependent ligand inhibition of the human organic cation transporter OCT2.
Belzer M; Morales M; Jagadish B; Mash EA; Wright SH
J Pharmacol Exp Ther; 2013 Aug; 346(2):300-10. PubMed ID: 23709117
[TBL] [Abstract][Full Text] [Related]
4. The multidrug transporter MATE1 sequesters OCs within an intracellular compartment that has no influence on OC secretion in renal proximal tubules.
Martínez-Guerrero LJ; Evans KK; Dantzler WH; Wright SH
Am J Physiol Renal Physiol; 2016 Jan; 310(1):F57-67. PubMed ID: 26538438
[TBL] [Abstract][Full Text] [Related]
5. Lack of Influence of Substrate on Ligand Interaction with the Human Multidrug and Toxin Extruder, MATE1.
Martínez-Guerrero LJ; Morales M; Ekins S; Wright SH
Mol Pharmacol; 2016 Sep; 90(3):254-64. PubMed ID: 27418674
[TBL] [Abstract][Full Text] [Related]
6. Cationic Compounds with SARS-CoV-2 Antiviral Activity and Their Interaction with Organic Cation Transporter/Multidrug and Toxin Extruder Secretory Transporters.
Martinez-Guerrero L; Zhang X; Zorn KM; Ekins S; Wright SH
J Pharmacol Exp Ther; 2021 Oct; 379(1):96-107. PubMed ID: 34253645
[TBL] [Abstract][Full Text] [Related]
7. Molecular determinants of ligand selectivity for the human multidrug and toxin extruder proteins MATE1 and MATE2-K.
Astorga B; Ekins S; Morales M; Wright SH
J Pharmacol Exp Ther; 2012 Jun; 341(3):743-55. PubMed ID: 22419765
[TBL] [Abstract][Full Text] [Related]
8. Assessment of Substrate-Dependent Ligand Interactions at the Organic Cation Transporter OCT2 Using Six Model Substrates.
Sandoval PJ; Zorn KM; Clark AM; Ekins S; Wright SH
Mol Pharmacol; 2018 Sep; 94(3):1057-1068. PubMed ID: 29884691
[TBL] [Abstract][Full Text] [Related]
9. Impact of Experimental Conditions on the Evaluation of Interactions between Multidrug and Toxin Extrusion Proteins and Candidate Drugs.
Lechner C; Ishiguro N; Fukuhara A; Shimizu H; Ohtsu N; Takatani M; Nishiyama K; Washio I; Yamamura N; Kusuhara H
Drug Metab Dispos; 2016 Aug; 44(8):1381-9. PubMed ID: 27271370
[TBL] [Abstract][Full Text] [Related]
10. Role of organic cation transporter OCT2 and multidrug and toxin extrusion proteins MATE1 and MATE2-K for transport and drug interactions of the antiviral lamivudine.
Müller F; König J; Hoier E; Mandery K; Fromm MF
Biochem Pharmacol; 2013 Sep; 86(6):808-15. PubMed ID: 23876341
[TBL] [Abstract][Full Text] [Related]
11. Multiple mechanisms of ligand interaction with the human organic cation transporter, OCT2.
Harper JN; Wright SH
Am J Physiol Renal Physiol; 2013 Jan; 304(1):F56-67. PubMed ID: 23034939
[TBL] [Abstract][Full Text] [Related]
12. Impact of Direction of Transport on the Evaluation of Inhibition Potencies of Multidrug and Toxin Extrusion Protein 1 Inhibitors.
Saito A; Ishiguro N; Takatani M; Bister B; Kusuhara H
Drug Metab Dispos; 2021 Feb; 49(2):152-158. PubMed ID: 33262224
[TBL] [Abstract][Full Text] [Related]
13. Molecular identification and functional characterization of rabbit MATE1 and MATE2-K.
Zhang X; Cherrington NJ; Wright SH
Am J Physiol Renal Physiol; 2007 Jul; 293(1):F360-70. PubMed ID: 17442726
[TBL] [Abstract][Full Text] [Related]
14. MATE1 has an external COOH terminus, consistent with a 13-helix topology.
Zhang X; Wright SH
Am J Physiol Renal Physiol; 2009 Aug; 297(2):F263-71. PubMed ID: 19515813
[TBL] [Abstract][Full Text] [Related]
15. Organic cation transporters OCT1, 2, and 3 mediate high-affinity transport of the mutagenic vital dye ethidium in the kidney proximal tubule.
Lee WK; Reichold M; Edemir B; Ciarimboli G; Warth R; Koepsell H; Thévenod F
Am J Physiol Renal Physiol; 2009 Jun; 296(6):F1504-13. PubMed ID: 19357179
[TBL] [Abstract][Full Text] [Related]
16. Interaction of human multidrug and toxin extrusion 1 (MATE1) transporter with antineoplastic agents.
Grottker J; Rosenberger A; Burckhardt G; Hagos Y
Drug Metabol Drug Interact; 2011; 26(4):181-9. PubMed ID: 22149660
[TBL] [Abstract][Full Text] [Related]
17. Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney.
Ito S; Kusuhara H; Yokochi M; Toyoshima J; Inoue K; Yuasa H; Sugiyama Y
J Pharmacol Exp Ther; 2012 Feb; 340(2):393-403. PubMed ID: 22072731
[TBL] [Abstract][Full Text] [Related]
18. Substrate-Dependent Inhibition of the Human Organic Cation Transporter OCT2: A Comparison of Metformin with Experimental Substrates.
Hacker K; Maas R; Kornhuber J; Fromm MF; Zolk O
PLoS One; 2015; 10(9):e0136451. PubMed ID: 26327616
[TBL] [Abstract][Full Text] [Related]
19. Involvement of Renal Efflux Transporter MATE1 in Renal Excretion of Flecainide.
Doki K; Apáti S; Sakata T; Homma M
Biol Pharm Bull; 2019; 42(7):1226-1229. PubMed ID: 31257298
[TBL] [Abstract][Full Text] [Related]
20. Correlation between Apparent Substrate Affinity and OCT2 Transport Turnover.
Severance AC; Sandoval PJ; Wright SH
J Pharmacol Exp Ther; 2017 Sep; 362(3):405-412. PubMed ID: 28615288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
